Search company, investor...
Search

Founded Year

2013

Stage

Reverse Merger | IPO

Total Raised

$345.55M

About BenevolentAI

BenevolentAI (AMS: BAI) creates and applies AI and machine learning to update the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process, from hypothesis generation to late-stage clinical development. The company was founded in 2013 and is based in London, England.

BenevolentAI Headquarters Location

4- 8 Maple Street

London, England, W1T 5HD,

United Kingdom

+44 (0) 20 3096 0720

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

BenevolentAI's Products & Differentiation

See BenevolentAI's products and how their products differentiate from alternatives and competitors

  • Target ID Collaboration

    Description: Maximise the opportunity to find novel drug targets for disease areas of interest, working with our cross-functional team of expert technologists, data scientists and drug discovery scientists

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing BenevolentAI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BenevolentAI in 12 CB Insights research briefs, most recently on Aug 22, 2022.

Expert Collections containing BenevolentAI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BenevolentAI is included in 4 Expert Collections, including Digital Health.

D

Digital Health

21,952 items

Startups recreating how healthcare is delivered

A

Artificial Intelligence

9,391 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharma Tech

838 items

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

BenevolentAI Patents

BenevolentAI has filed 24 patents.

The 3 most popular patent topics include:

  • Machine learning
  • Bioinformatics
  • Biological databases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2019

6/22/2021

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins

Grant

Application Date

7/17/2019

Grant Date

6/22/2021

Title

Related Topics

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins

Status

Grant

Latest BenevolentAI News

Babylon, BenevolentAI, Deliveroo and Darktrace: the UK’s first generation of tech darlings hit choppy water

Sep 26, 2022

As Babylon implements a reverse share split to stay on the NYSE, Sifted looks at how other now publicly listed British tech giants are faring Babylon, BenevolentAI, Deliveroo and Darktrace: the UK’s first generation of tech darlings hit choppy water

BenevolentAI Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BenevolentAI Rank

  • When was BenevolentAI founded?

    BenevolentAI was founded in 2013.

  • Where is BenevolentAI's headquarters?

    BenevolentAI's headquarters is located at 4- 8 Maple Street, London.

  • What is BenevolentAI's latest funding round?

    BenevolentAI's latest funding round is Reverse Merger.

  • How much did BenevolentAI raise?

    BenevolentAI raised a total of $345.55M.

  • Who are the investors of BenevolentAI?

    Investors of BenevolentAI include Odyssey Acquisition, Tech Nation Fintech, Temasek, Woodford Investment Management, H. Lundbeck and 4 more.

  • Who are BenevolentAI's competitors?

    Competitors of BenevolentAI include Insilico Medicine, DEARGEN, Terray Therapeutics, Biotx.ai, Diagu, Exscientia, XtalPi, BioMap, Standigm, AliveX and 23 more.

  • What products does BenevolentAI offer?

    BenevolentAI's products include Target ID Collaboration and 2 more.

  • Who are BenevolentAI's customers?

    Customers of BenevolentAI include AstraZeneca.

You May Also Like

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions that transform the way innovative medicines and treatments are discovered and accelerate research and development. The company was founded in 2014 and is based in Hong Kong.

Atomwise Logo
Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

insitro Logo
insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Healx Logo
Healx

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.

Cyclica Logo
Cyclica

Cyclica is a global biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica's structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.

Standigm Logo
Standigm

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.